Table of contents
- Clinical trials overview
- Phase I/IIa study in advanced solid malignancies
- Phase III study in endometrial cancer
- Who can participate
- What the trials measure
- Key patient terms
Clinical trials overview
The available trial data show two studies of Azd8205 in cancer patients.[1][2] One is a completed early study in advanced or metastatic solid malignancies, and the other is an authorised Phase III study in B7-H4-selected advanced or metastatic endometrial cancer.[1][2]
These trials are not general medicine studies.[1][2] They are focused on specific cancer groups and are designed to test safety, dose, and treatment benefit.[1][2]
Phase I/IIa study in advanced solid malignancies
The first study was a Phase I/IIa interventional trial and is now completed.[1] It enrolled 183 participants with advanced or metastatic solid cancers.[1]
This study looked at Azd8205 as monotherapy, which means treatment with Azd8205 alone, and also in combination with other anticancer drugs.[1] The brief summary says the main goals were to assess safety and tolerability and to find the maximum tolerated dose and/or the recommended Phase 2 dose.[1]
These goals are typical for an early cancer trial.[1] In simple terms, the researchers wanted to learn how much treatment could be given safely and what dose should be studied next.[1]
Phase III study in endometrial cancer
The second study is a global Phase III trial and is authorised.[2] It studies Puxitatug Samrotecan (Azd8205) as monotherapy compared with physician’s choice of chemotherapy in B7-H4-selected endometrial cancer that progressed after platinum-based chemotherapy and anti-PD-1 or anti-PD-L1 therapy.[2]
The trial plans to enroll 701 participants.[2] The chemotherapy choices listed in the source are paclitaxel and doxorubicin.[2]
This study is later-stage research, so it is mainly designed to compare outcomes between treatment groups.[2] It is not focused on dose-finding, but on whether Azd8205 can improve important cancer outcomes compared with standard chemotherapy.[2]
Who can participate
The completed Phase I/IIa study included participants with advanced or metastatic solid malignancies.[1] That means people had cancers that were advanced, had spread, or both.[1]
The Phase III study is narrower and is for people with B7-H4-selected advanced/metastatic endometrial cancer.[2] The cancer must also have progressed after platinum-based chemotherapy and anti-PD-1/anti-PD-L1 therapy.[2]
“Selected” means the trial uses a specific cancer marker, B7-H4, to choose the study group.[2] This helps researchers study Azd8205 in a more defined patient population.[2]
What the trials measure
In the Phase I/IIa study, the main focus was safety, tolerability, the maximum tolerated dose, and the recommended Phase 2 dose.[1] Safety means whether the treatment can be given without causing unacceptable harm.[1] Tolerability means how well people can handle the treatment.[1]
In the Phase III study, the main outcomes are progression-free survival and overall survival.[2] Progression-free survival is the time until the cancer gets worse or the person dies.[2] Overall survival is the time until death from any cause.[2]
The Phase III trial defines progression by RECIST 1.1 and uses BICR, which means blinded independent central review.[2] In simple words, this is a careful and unbiased way to check whether the cancer has grown.[2]
Key patient terms
Interventional trial means the researchers give a treatment and then measure the results.[1][2]
Monotherapy means one treatment only, while combination therapy means more than one treatment together.[1]
Physician’s choice of chemotherapy means the doctor chooses from the study’s listed standard chemotherapy options.[2]
Endometrial cancer is cancer that starts in the lining of the uterus.[2]
